Carbon tetrachloride-induced acute liver toxicity: selecting dosage and biomarkers for evaluating hepatoprotective drugs in ICR outbred mice

Q4 Pharmacology, Toxicology and Pharmaceutics
Theerut Luangmonkon, Chanitkarn Pransin, Ladawan Nopphalee, Sirada Meechai, Suprawee Chunya, Atis Rattanavaraha, Naphat Kaewnoppharat, Thayida Khuituan, Sanpetch Bunyakiat, W. Parichatikanond
{"title":"Carbon tetrachloride-induced acute liver toxicity: selecting dosage and biomarkers for evaluating hepatoprotective drugs in ICR outbred mice","authors":"Theerut Luangmonkon, Chanitkarn Pransin, Ladawan Nopphalee, Sirada Meechai, Suprawee Chunya, Atis Rattanavaraha, Naphat Kaewnoppharat, Thayida Khuituan, Sanpetch Bunyakiat, W. Parichatikanond","doi":"10.29090/psa.2022.06.22.212","DOIUrl":null,"url":null,"abstract":"Evaluating effects of putative chemical or herbal agents against a single intraperitoneal administration of carbon tetrachloride (CCl 4 ) in rodents is a widely used model for studying hepatoprotective potency. Since the toxic effects of CCl 4 is dependent on individual species; therefore, our study aimed to demonstrate a procedure to select the optimal dosage of CCl 4 and types of liver damage-associated biomarkers for testing hepatoprotective drugs in ICR mice. To include inter-individual genetic variation, the test was conducted in outbred mice. Silymarin and rebamipide were applied as the representative tested agents. We revealed that 15-150  L/kg of CCl 4 induced liver damage including hepatocyte vacuolation and ballooning with infiltration of inflammatory cells, centrilobular necrosis, and increased serum alanine aminotransferase and aspartate aminotransferase, in a dosage-dependent manner. Nonetheless, serum levels of bilirubin were not significantly increased at 15  L/kg of CCl 4 . On the other hands, the level of alkaline phosphatase was not parallel with the increased dosage of CCl 4 . Most importantly, as observed using liver histology and serum biomarkers, rebamipide and silymarin showed hepatoprotective effects against 15  L/kg of CCl 4 merely, whereas both drugs were unable to protect liver injury against 150  L/kg of CCl 4 . In conclusion, this study demonstrated how to design an experiment to select the optimal dosage of CCl 4 for evaluating hepatoprotective effects of putative agents in a specific tested species. In addition, we revealed choices of serum biomarkers which could be associated with the severity of liver damage.","PeriodicalId":19761,"journal":{"name":"Pharmaceutical Sciences Asia","volume":"44 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Sciences Asia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29090/psa.2022.06.22.212","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 1

Abstract

Evaluating effects of putative chemical or herbal agents against a single intraperitoneal administration of carbon tetrachloride (CCl 4 ) in rodents is a widely used model for studying hepatoprotective potency. Since the toxic effects of CCl 4 is dependent on individual species; therefore, our study aimed to demonstrate a procedure to select the optimal dosage of CCl 4 and types of liver damage-associated biomarkers for testing hepatoprotective drugs in ICR mice. To include inter-individual genetic variation, the test was conducted in outbred mice. Silymarin and rebamipide were applied as the representative tested agents. We revealed that 15-150  L/kg of CCl 4 induced liver damage including hepatocyte vacuolation and ballooning with infiltration of inflammatory cells, centrilobular necrosis, and increased serum alanine aminotransferase and aspartate aminotransferase, in a dosage-dependent manner. Nonetheless, serum levels of bilirubin were not significantly increased at 15  L/kg of CCl 4 . On the other hands, the level of alkaline phosphatase was not parallel with the increased dosage of CCl 4 . Most importantly, as observed using liver histology and serum biomarkers, rebamipide and silymarin showed hepatoprotective effects against 15  L/kg of CCl 4 merely, whereas both drugs were unable to protect liver injury against 150  L/kg of CCl 4 . In conclusion, this study demonstrated how to design an experiment to select the optimal dosage of CCl 4 for evaluating hepatoprotective effects of putative agents in a specific tested species. In addition, we revealed choices of serum biomarkers which could be associated with the severity of liver damage.
四氯化碳诱导的急性肝毒性:选择剂量和生物标志物评估ICR远交种小鼠的肝保护药物
评估假定的化学或草药制剂对啮齿类动物单次腹腔注射四氯化碳(ccl4)的影响是研究肝保护效力的一种广泛使用的模型。由于ccl4的毒性作用取决于个体物种;因此,我们的研究旨在展示一种方法来选择ccl4的最佳剂量和肝损伤相关生物标志物的类型,以测试ICR小鼠的肝保护药物。为了包括个体间的遗传变异,该试验在近亲繁殖的小鼠中进行。以水飞蓟素和利巴米胺为代表性试验剂。我们发现,15-150L/kg的cccl可诱导肝损伤,包括肝细胞空泡化和球囊化,伴有炎症细胞浸润,小叶中心坏死,血清丙氨酸转氨酶和天冬氨酸转氨酶升高,并呈剂量依赖性。然而,血清胆红素水平在15L/kg cccl浓度下没有显著升高。另一方面,碱性磷酸酶水平与ccl4用量的增加不平行。最重要的是,通过肝脏组织学和血清生物标志物观察,利巴米胺和水飞蓟素仅对15L/kg的cccl有肝保护作用,而对150L/kg的cccl,这两种药物都不能保护肝损伤。总之,本研究展示了如何设计一个实验来选择CCl - 4的最佳剂量,以评估特定被试物种中可能的药物的肝保护作用。此外,我们还揭示了可能与肝损伤严重程度相关的血清生物标志物的选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmaceutical Sciences Asia
Pharmaceutical Sciences Asia Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
0.90
自引率
0.00%
发文量
59
期刊介绍: The Pharmaceutical Sciences Asia (PSA) journal is a double-blinded peer-reviewed journal in English published quarterly, by the Faculty of Pharmacy, Mahidol University, Thailand. The PSA journal is formerly known as Mahidol University Journal of Pharmaceutical Sciences and committed to the timely publication of innovative articles and reviews. This journal is available in both printed and electronic formats. The PSA journal aims at establishing a publishing house that is open to all. It aims to disseminate knowledge; provide a learned reference in the field; and establish channels of communication between academic and research expert, policy makers and executives in industry and investment institutions. The journal publishes research articles, review articles, and scientific commentaries on all aspects of the pharmaceutical sciences and multidisciplinary field in health professions and medicine. More specifically, the journal publishes research on all areas of pharmaceutical sciences and related disciplines: Clinical Pharmacy Drug Synthesis and Discovery Targeted-Drug Delivery Pharmaceutics Biopharmaceutical Sciences Phytopharmaceutical Sciences Pharmacology and Toxicology Pharmaceutical Chemistry Nutraceuticals and Functional Foods Natural Products Social, Economic, and Administrative Pharmacy Clinical Drug Evaluation and Drug Policy Making Antimicrobials, Resistance and Infection Control Pharmacokinetics and Pharmacodynamics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信